^
    over1year
    Efficacy of osimertinib in patients with lung cancer positive for uncommon EGFR exon 19 deletion mutations. (PubMed, Clin Cancer Res)
    The ex19del L747_A750>P is associated with inferior PFS compared to the common E746_A750del mutation in patients treated with 1L osimertinib. Understanding differences in osimertinib efficacy among EGFR ex19del.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 19 deletion • EGFR T790M • EGFR E746 • EGFR L747_A750>P
    |
    Tagrisso (osimertinib)
    over2years
    Ad hoc afatinib in an eldery lung cancer patient with EGFR exon 19 deletion L747-A750>P. (PubMed, Adv Respir Med)
    No abstract available
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR exon 19 deletion • EGFR L747_A750>P
    |
    Gilotrif (afatinib)
    over2years
    Efficacy of osimertinib in patients with EGFR mutant lung cancer harboring the uncommon exon 19 deletion, L747_A750>P. (ASCO 2022)
    The del19 mutation L747_A750 > P is associated with inferior PFS compared to the common E746_A750del mutation in pts treated with 1L osimertinib. Understanding differences in osimertinib efficacy among EGFR del19 subtypes could alter management of these pts in the future.
    Clinical
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 19 deletion • EGFR T790M • EGFR E746_A750del • EGFR E746 • EGFR L747_A750>P
    |
    Tagrisso (osimertinib)